lobbying_filings_raw: d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | amount_reported | is_amendment | is_no_activity | is_termination | raw_json |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6 | Q2 | 400693064 | RED+BLUE STRATEGIES | 194273 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2017 | second_quarter | 2017-07-10T14:04:59.903000-04:00 | 60000.0 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6/", "filing_uuid": "d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6", "filing_type": "Q2", "filing_type_display": "2nd Quarter - Report", "filing_year": 2017, "filing_period": "second_quarter", "filing_period_display": "2nd Quarter (Apr 1 - June 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6/print/", "filing_document_content_type": "text/html", "income": "60000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Melanie Nathanson", "dt_posted": "2017-07-10T14:04:59.903000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "601 13th Street NW", "registrant_address_2": "11th Floor North", "registrant_different_address": false, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20005", "registrant": {"id": 400693064, "url": "https://lda.senate.gov/api/v1/registrants/400693064/", "house_registrant_id": null, "name": "RED+BLUE STRATEGIES", "description": "Health Care Consulting", "address_1": "975 F St NW", "address_2": "Suite 550", "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20004", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "MELANIE NATHANSON", "contact_telephone": "+1 202-258-9381", "dt_updated": "2026-02-25T17:01:10.141217-05:00"}, "client": {"id": 194273, "url": "https://lda.senate.gov/api/v1/clients/194273/", "client_id": 51, "name": "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", "general_description": "PCMA represents pharmacy benefit managers, who administer the nation's covered Rx benefits", "client_government_entity": false, "client_self_select": false, "state": "DC", "state_display": "District of Columbia", "country": "US", "country_display": "United States of America", "ppb_state": null, "ppb_state_display": null, "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2011-01-14"}, "lobbying_activities": [{"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \n\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. \n\nS. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. \n\nH.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. \n\nIssues related to the price of prescription medications in the United States.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 54544, "prefix": "ms", "prefix_display": "MS.", "first_name": "MELANIE", "nickname": null, "middle_name": "JAN", "last_name": "NATHANSON", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 145382, "prefix": "ms", "prefix_display": "MS.", "first_name": "MEGAN", "nickname": null, "middle_name": "HAUCK", "last_name": "MARSHALL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 11, "name": "Executive Office of the President (EOP)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 18, "name": "Office of Management & Budget (OMB)"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \n\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. \n\nIssues related to the cost of prescription medications in the Medicare and Medicaid programs.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 54544, "prefix": "ms", "prefix_display": "MS.", "first_name": "MELANIE", "nickname": null, "middle_name": "JAN", "last_name": "NATHANSON", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 145382, "prefix": "ms", "prefix_display": "MS.", "first_name": "MEGAN", "nickname": null, "middle_name": "HAUCK", "last_name": "MARSHALL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 11, "name": "Executive Office of the President (EOP)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 18, "name": "Office of Management & Budget (OMB)"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \n\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. \n\nS. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. \n\nH.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. \n\nIssues related to the price of prescription medications in the United States.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 54544, "prefix": "ms", "prefix_display": "MS.", "first_name": "MELANIE", "nickname": null, "middle_name": "JAN", "last_name": "NATHANSON", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 145382, "prefix": "ms", "prefix_display": "MS.", "first_name": "MEGAN", "nickname": null, "middle_name": "HAUCK", "last_name": "MARSHALL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 11, "name": "Executive Office of the President (EOP)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 18, "name": "Office of Management & Budget (OMB)"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} |